Suven Life Sciences Ltd has been granted three product patents.
The patents—one each from Australia, South Korea and China—are for its New Chemical Entities for the treatment of disorders associated with neurodegenerative diseases.
The granted claims of the patents include the class of select alpha-4-beta-2 compounds discovered by Suven and are being developed as therapeutic agents for major depressive disorder, the Hyderabad-based company said in a release issued on Monday.
With these new patents, Suven has a total of seventeen (17) granted patents from Australia, thirteen granted patents from South Korea and thirteen (13) product patents from China.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.